XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Restatement of Previously Issued Financial Statements - Consolidated Cash Flow Statements (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2022
Dec. 31, 2021
Sep. 30, 2021
Jun. 30, 2021
Sep. 30, 2021
Dec. 31, 2021
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2021
Cash flows from operating activities:                  
Net income $ 5,540 $ 3,823 $ 5,774 $ 3,579 $ 9,353 $ 13,176 $ 5,140 $ 18,716 $ 23,919
Adjustments to reconcile net income to net cash provided by operating activities:                  
Depreciation             3,546 2,738 2,427
Share based compensation             6,617 4,549 3,307
Deferred income taxes       (353) 11 (473) (1,630) (846) (1,273)
Bad debt expense             214 165 130
(Increase) decrease in operating assets and increase (decrease) in liabilities:                  
Accounts receivable             (41) 509 1,126
Inventories - finished goods             13,432 1,965 (16,536)
Prepaid income taxes             (182) 278 (959)
Prepaid expenses and other current assets             147 (363) (974)
Accounts payable             (2,292) (12,048) 19,890
Sales tax payable       1,035 1,759 2,312 1,956 2,928 8,268
Accrued expenses and other current liabilities           896 (93) 1,221
Income taxes payable             0 0 (471)
Net cash provided by operating activities             27,803 18,498 40,075
Cash flows from investing activities:                  
Purchase of minority interest investment in Vetster             (5,000) 0 0
Purchases of property and equipment             (5,260) (1,752) (2,432)
Net cash used in investing activities             (10,260) (1,752) (2,432)
Cash flows from financing activities:                  
Dividends paid             (24,537) (24,384) (22,687)
Net cash used in financing activities             (24,537) (24,384) (22,687)
Net (decrease) increase in cash and cash equivalents             (6,994) (7,638) 14,956
Cash and cash equivalents, at beginning of year       118,718 118,718 118,718 111,080 118,718 103,762
Cash and cash equivalents, at end of year 111,080           104,086 111,080 118,718
Supplemental disclosure of cash flow information:                  
Cash paid for income taxes             4,312 6,085 10,018
Dividends payable in accrued expenses             1,262 558 198
As previously reported                  
Cash flows from operating activities:                  
Net income 6,066 4,257 6,349 4,428 10,777 15,034 233 21,100 30,603
Adjustments to reconcile net income to net cash provided by operating activities:                  
Depreciation             3,546 2,738 2,427
Share based compensation             6,617 4,549 3,307
Deferred income taxes       (167) 346 (19) (1,564) (345) 311
Bad debt expense             214 165 130
(Increase) decrease in operating assets and increase (decrease) in liabilities:                  
Accounts receivable             (41) 509 1,126
Inventories - finished goods             13,432 1,965 (16,536)
Prepaid income taxes             (1,202) 278 (959)
Prepaid expenses and other current assets             147 (363) (974)
Accounts payable             (2,292) (12,048) 19,890
Sales tax payable       0 0 0 0 0 0
Accrued expenses and other current liabilities           8,713 (50) 1,221
Income taxes payable                 (471)
Net cash provided by operating activities             27,803 18,498 40,075
Cash flows from investing activities:                  
Purchase of minority interest investment in Vetster             (5,000) 0 0
Purchases of property and equipment             (5,260) (1,752) (2,432)
Net cash used in investing activities             (10,260) (1,752) (2,432)
Cash flows from financing activities:                  
Dividends paid             (24,537) (24,384) (22,687)
Net cash used in financing activities             (24,537) (24,384) (22,687)
Net (decrease) increase in cash and cash equivalents             (6,994) (7,638) 14,956
Cash and cash equivalents, at beginning of year       118,718 118,718 118,718 111,080 118,718 103,762
Cash and cash equivalents, at end of year 111,080           104,086 111,080 118,718
Supplemental disclosure of cash flow information:                  
Cash paid for income taxes             4,312 6,085 10,018
Dividends payable in accrued expenses             1,262 558 198
Restatement Adjustments                  
Cash flows from operating activities:                  
Net income (526) $ (434) $ (575) (849) (1,424) (1,858) 4,907 (2,384) (6,684)
Adjustments to reconcile net income to net cash provided by operating activities:                  
Depreciation             0 0 0
Share based compensation             0 0 0
Deferred income taxes       (186) (335) (454) (66) (501) (1,584)
Bad debt expense             0 0 0
(Increase) decrease in operating assets and increase (decrease) in liabilities:                  
Accounts receivable             0 0 0
Inventories - finished goods             0 0 0
Prepaid income taxes             1,020 0 0
Prepaid expenses and other current assets             0 0 0
Accounts payable             0 0 0
Sales tax payable       1,035 1,759 2,312 1,956 2,928 8,268
Accrued expenses and other current liabilities           (7,817) (43) 0
Income taxes payable                 0
Net cash provided by operating activities             0 0 0
Cash flows from investing activities:                  
Purchase of minority interest investment in Vetster             0 0 0
Purchases of property and equipment             0 0 0
Net cash used in investing activities             0 0 0
Cash flows from financing activities:                  
Dividends paid             0 0 0
Net cash used in financing activities             0 0 0
Net (decrease) increase in cash and cash equivalents             0 0 0
Cash and cash equivalents, at beginning of year       $ 0 $ 0 $ 0 0 0 0
Cash and cash equivalents, at end of year $ 0           0 0 0
Supplemental disclosure of cash flow information:                  
Cash paid for income taxes             0 0 0
Dividends payable in accrued expenses             $ 0 $ 0 $ 0